PMGC HOLDINGS INC. Marketing and Advertising Expense
PMGC HOLDINGS INC. (ELAB) reported Marketing and Advertising Expense of $25.40 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:MarketingAndAdvertisingExpense · last filed 2026-08-14
- PMGC HOLDINGS INC. marketing and advertising expense for the quarter ending 2026-06-30 was $25.40K, a 69.14% decline year-over-year.
- PMGC HOLDINGS INC. marketing and advertising expense for the quarter ending 2026-03-31 was $34.36K, a 3.46% decline year-over-year.
- PMGC HOLDINGS INC. marketing and advertising expense for the quarter ending 2025-12-31 was $18.53K, a 14.75% increase year-over-year.
- PMGC HOLDINGS INC. marketing and advertising expense for the quarter ending 2025-09-30 was $64.48K, a 472.78% increase year-over-year.
- PMGC HOLDINGS INC. marketing and advertising expense for fiscal 2025 was $200.94K, a 31.31% decline from fiscal 2024.
- PMGC HOLDINGS INC. marketing and advertising expense for fiscal 2024 was $292.52K, a 14.07% increase from fiscal 2023.
- PMGC HOLDINGS INC. marketing and advertising expense for fiscal 2023 was $256.45K, a 602.58% increase from fiscal 2022.
- PMGC HOLDINGS INC. marketing and advertising expense for fiscal 2022 was $36.50K.
| Period end | Marketing and Advertising Expense 3 month | Marketing and Advertising Expense 3 month as first filed | Marketing and Advertising Expense 6 month | Marketing and Advertising Expense 9 month | Marketing and Advertising Expense 9 month as first filed | Marketing and Advertising Expense 12 month | Marketing and Advertising Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $25.40K 10-Q · filed 2026-08-14 | $59.77K 10-Q · filed 2026-08-14 | $78.30K derived: sum of 3 quarters · filed 2026-08-14 | $142.78K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $34.36K 10-Q · filed 2026-05-15 | $52.90K derived: sum of 2 quarters · filed 2026-05-15 | $117.38K derived: sum of 3 quarters · filed 2026-05-15 | $199.71K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $18.53K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $83.02K derived: sum of 2 quarters · filed 2026-03-30 | $165.35K derived: sum of 3 quarters · filed 2026-08-14 | $200.94K 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $64.48K 10-Q · filed 2025-11-14 | $146.81K derived: sum of 2 quarters · filed 2026-08-14 | $182.41K 10-Q · filed 2025-11-14 | $198.56K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $82.33K 10-Q · filed 2026-08-14 | $117.92K 10-Q · filed 2026-08-14 | $134.07K derived: sum of 3 quarters · filed 2026-08-14 | $145.33K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $35.59K 10-Q · filed 2026-05-15 | $51.74K derived: sum of 2 quarters · filed 2026-05-15 | $63.00K derived: sum of 3 quarters · filed 2026-05-15 | $196.60K derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | $16.15K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $27.41K derived: sum of 2 quarters · filed 2026-03-30 | $161.01K derived: sum of 3 quarters · filed 2026-03-30 | $292.52K 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $11.26K 10-Q · filed 2025-11-14 | $94.51K 10-Q · filed 2024-11-14 | $144.85K derived: sum of 2 quarters · filed 2025-11-14 | $276.37K 10-Q · filed 2025-11-14 | $1.21M 10-Q · filed 2024-11-14 | $216.38K derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $133.60K 10-Q · filed 2025-08-13 | $265.11K 10-Q · filed 2025-08-13 | $205.13K derived: sum of 3 quarters · filed 2025-08-13 | $304.84K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $131.52K 10-Q · filed 2025-05-14 | $71.53K derived: sum of 2 quarters · filed 2025-05-14 | $171.24K derived: sum of 3 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | -$59.99K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $39.72K derived: sum of 2 quarters · filed 2025-03-28 | $256.45K 10-K · filed 2025-03-28 | $124.38K 10-K · filed 2024-03-29 | |||
| 2023-09-30 | $99.71K 10-Q · filed 2024-11-14 | $316.44K 10-Q · filed 2024-11-14 | $96.18M 10-Q · filed 2023-12-11 | ||||
| 2022-12-31 | -$29.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $36.50K 10-K · filed 2024-03-29 | |||||
| 2022-09-30 | $29.44M 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |